Changes in opioid treatment programs and harm reduction provider services during the COVID-19 pandemic: Findings from 10 states.  Heidari O, Shah H, Bhagwat A, Ahmad NJ, Whaley S, Sherman SG, Morris M, Saloner B.  Psychol Serv. 2023 Oct 12…

Methadone use for acute opioid withdrawal in Tshwane shelters during the COVID-19 lockdown.  Siemens JA, Bhoora U, Janse van Rensburg M.  S Afr Fam Pract (2004). 2023 Sep 5;65(1):e1-e7. doi: 10.4102/safp.v65i1.5708. PMID: 37916694; PM…

Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021.  Meyerson BE, Russell DM, Downer M, Alfar A, Garnett I, Lowther J, Lut…

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.  Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, Lofwall MR, Nau M, Villani J, Walsh SL, Westgate PM, Slavo…

Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.  Mitchell SG, Jester J, Gryczynski J, Whitter M, Fuller D, Halsted C, Schwartz RP.  Addict Sci Clin Pract. 2023 O…

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.  Adams A, Blawatt S, Magel T, MacDonald S, Lajeu…